Haemonetics Q1 2027 Earnings Call Transcript
Haemonetics reported strong Q1 fiscal 2027 results with 6% revenue growth and a 4% increase in adjusted EPS. The company raised its full-year guidance, driven by robust performance in MedSurg and Apheresis segments, particularly plasma revenue and the Persona Plus rollout. Strategic investments, portfolio enhancements, and commercial execution are expected to sustain long-term growth and strong cash flow.
Haemonetics stock heads into November 5 results with key benchmarks
Haemonetics (HAE) stock is approaching its fiscal Q2 2027 results on November 5, 2026, after reporting strong fiscal Q1 revenue and adjusted EPS that surpassed consensus estimates. The stock closed at $104.68 on October 2, 2026, below the average analyst price target of $99.78, but some analysts have more optimistic targets. The upcoming report will be crucial for valuation given the spread between the average target and the current share price.
BTIG reiterates Buy rating on Haemonetics with $84 target
BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics (HAE) and maintained a price target of $84, signaling continued confidence in the company's stock performance. This reaffirmation follows a previous report where both Mizuho and BTIG expressed positive outlooks on Haemonetics, with Mizuho raising its price target to $85. The analyst ratings provide specific benchmarks for investors regarding the stock's valuation expectations.
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026
Haemonetics Corporation (NYSE: HAE) announced its plan to release second quarter fiscal year 2027 financial results on Thursday, November 5, 2026, at 6:00 am ET. The company will host a conference call for investors and analysts at 8:00 am ET on the same day to discuss the results and answer questions. A live webcast and replay of the call will be accessible via Haemonetics' investor relations website.
Haemonetics sets Q2FY27 earnings release date for November 5
Haemonetics Corporation (NYSE: HAE) announced it will release its second quarter fiscal year 2027 financial results on November 5, 2026, at 6:00 am ET. The company will also host a conference call for investors and analysts at 8:00 am ET on the same day to discuss the results and answer questions, with a webcast replay available for one year.
Precision Trading with Haemonetics Corporation (HAE) Risk Zones
This article provides a detailed analysis of Haemonetics Corporation (HAE) with a focus on precision trading using AI-generated risk zones and trading strategies. It highlights weak near-term sentiment but compelling upside potential due to the absence of resistance levels above the current price. The report offers specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
HAE6089008 Bond Profile: Coupon and Redemption
This article provides a detailed bond profile for Haemonetics Corporation's HAE6089008 bond, highlighting its coupon and redemption information. It covers key facts such as issuer type, issue and maturity dates, face value, and minimum denomination. The profile also includes details on interest payments, a semi-annual fixed rate coupon of 2.50%, and the upcoming coupon payout schedule.
Haemonetics Corporation (HAE) Stock Price, News, Quote & History
Haemonetics Corporation (HAE) is a medical technology company specializing in hospital solutions, including plasma and blood center products, and various hospital products. The article provides current stock performance, key financial metrics, an overview of its operations, and recent analyst ratings. The stock closed at $106.00 with a slight decrease but has shown significant year-to-date and one-year returns.
HAE - Haemonetics Corp Volatility & Greeks
This article provides a detailed financial snapshot of Haemonetics Corp (HAE), including its last closing price, aftermarket activity, and key financial metrics. It covers various performance indicators such as market capitalization, income, sales, earnings per share, and price ratios, alongside volatility measures and short interest data. The information is presented as of September 23rd, with a focus on comprehensive company data for investors.
Haemonetics stock hits 52-week high at 109.6 USD
Haemonetics (HAE) stock reached a new 52-week high of $109.60, demonstrating a 113.45% increase over the past year. The company's recent strong fiscal first-quarter results, surpassing Wall Street expectations, and a supply agreement with CSL Plasma Inc. contribute to this positive performance. InvestingPro analysis indicates the stock trades below its Fair Value and has a "GREAT" financial health score.
HAE Upgraded by Citigroup -- Price Target Raised to $123
Citigroup upgraded Haemonetics (HAE) to a "Buy" rating, raising its price target to $123 from $92.00, indicating optimism for the company's future performance in the healthcare sector. Despite the upgrade and a strong GF Score™ of 79/100, GuruFocus considers HAE modestly overvalued, trading 26.3% above its GF Value™ of $85.85. The company exhibits strong profitability and growth potential, but its momentum rank is lower, and its P/E ratio is significantly above its 5-year median.
Haemonetics Shares Rise After Citigroup Upgrade
Haemonetics shares increased after Citigroup upgraded the stock to "buy" from "neutral." The upgrade is based on the company's strong capital deployment, successful product launches, and potential for growth in its blood management and surgical businesses, with an increased price target of $105.
Haemonetics stock hits 52-week high at 109.6 USD By Investing.com
Haemonetics (HAE) stock has reached a new 52-week high of $109.60, marking a significant increase of 113.45% over the past year. This surge is attributed to strong investor confidence, positive market performance, and the company's recent impressive fiscal first-quarter results. InvestingPro analysis indicates the stock trades below its Fair Value and has a "GREAT" financial health score, with additional exclusive tips available for subscribers.
New Hope's Orchestra BioMed Receives $6.1 Million Milestone Payment from Vivasure-Haemonetics Deal
Orchestra BioMed Holdings, Inc. announced a $6.1 million milestone payment from Haemonetics Corporation, linked to Haemonetics' acquisition of Vivasure Medical. This payment, along with an earlier upfront sum, brings Orchestra BioMed's total proceeds from the deal to approximately $11 million, with potential for an additional $10 million in future earnouts. The funds will support Orchestra BioMed's pivotal clinical trials for its two flagship product candidates, AVIM Therapy for hypertension and Virtue® SAB for various vascular diseases.
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Orchestra BioMed announced it received a $6.1 million milestone payment from the acquisition of Vivasure Medical by Haemonetics. This payment, combined with a previous $5 million, brings the total cash proceeds to approximately $11 million. The company remains eligible for up to an additional $10 million in future revenue earnouts, totaling a potential of $21 million from its strategic holding in Vivasure.
Orchestra BioMed Obtains $6.1 Million Milestone Payment From Haemonetics' Acquisition of Vivasure
Orchestra BioMed has received a $6.1 million milestone payment from Haemonetics following its acquisition of Vivasure. This payment is part of an existing agreement related to the acquisition. The news was published by MT Newswires.
Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics
Orchestra BioMed announced it received a $6.1 million milestone payment following the acquisition of Vivasure Medical by Haemonetics, bringing its total cash proceeds from the deal to approximately $11 million. The company remains eligible for up to an additional $10 million in future revenue earnouts. This payment further supports Orchestra BioMed's strategic initiatives and pivotal programs.
Q1 2027 Haemonetics Corp Earnings Call Transcript
Haemonetics Corp reported strong Q1 2027 results with revenue up 6% and raised its full-year guidance, driven by growth in MedSurg and Plasma segments. The company demonstrated exceptional cash flow, despite a decline in adjusted operating margin due to cost pressures and slower growth in Interventional Technologies. The earnings call details positive momentum in various segments and outlines financial performance for the quarter.
Haemonetics (HAE) Q1 2026 Earnings: Results, Market Reaction & History
Haemonetics (HAE) reported strong Q1 2026 earnings, beating EPS and revenue estimates, with organic growth significantly improving after excluding divestitures. Despite positive financial results and reaffirmed full-year guidance, shares fell due to investor concerns about a slowdown in the Vascular Closure business. The company highlighted margin expansion driven by pricing benefits and favorable product mix across its segments.
Earnings Preview: Haemonetics (HAE) Q1 Earnings Expected to Decline
Haemonetics (HAE) is anticipated to report a year-over-year decline in earnings but higher revenues for the quarter ended June 2026. The Zacks Consensus Estimate for EPS is $1.07, down 2.7% from the prior year, with revenues expected to be $327.95 million, up 2%. The company's Earnings ESP is -4.67% and it holds a Zacks Rank of #4, making it difficult to confidently predict an earnings beat.
Robert W. Baird Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price
Robert W. Baird has raised its price target for Haemonetics (NYSE:HAE) to $119 from $96, maintaining an "outperform" rating, which suggests a potential upside of 9.74%. This positive forecast aligns with a broader "Moderate Buy" consensus among analysts, with Haemonetics also reporting strong quarterly earnings that surpassed expectations. Institutional ownership in the medical instruments supplier is significant, with 99.67% of shares held by such investors.
26,280 Shares in Haemonetics Corporation $HAE Acquired by Nierenberg Investment Management Company LLC
Nierenberg Investment Management Company LLC has acquired 26,280 shares of Haemonetics Corporation (NYSE:HAE) valued at approximately $1.97 billion, making it their 15th largest holding. This acquisition comes amid positive investor sentiment for Haemonetics, driven by a new supply agreement with CSL Plasma, strong quarterly results with raised revenue-growth forecasts, and recent analyst upgrades. The company's stock opened at $108.39, near its 12-month high, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $95.00.
Haemonetics stock hits 52-week high at 106.64 USD
Haemonetics Corp (NYSE:HAE) stock has reached a new 52-week high of $106.64, driven by a 92.73% 1-year return and strong recent performance. This surge follows robust fiscal first-quarter results that surpassed analyst expectations and a new supply agreement with CSL Plasma Inc. Despite this, InvestingPro analysis indicates the shares may be overvalued, though six analysts have revised earnings estimates upwards for the upcoming period.
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE
Aurora Investment Counsel recently acquired a new position in Haemonetics Corporation (NYSE:HAE), purchasing 25,501 shares valued at approximately $1.9 million. This investment comes as Haemonetics has exceeded quarterly expectations, with management raising its full-year revenue-growth outlook, and analysts maintaining a "Moderate Buy" consensus rating for the stock. The company also recently signed a new supply agreement with CSL Plasma, further bolstering positive sentiment.
HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $118 FROM $95
Barrington Research has increased its target price for Haemonetics Corp (HAE.N) to $118 from $95. This brief report, sourced from Reuters, indicates an updated valuation for the company's stock. The article explicitly states that its content reflects the author's opinion and is not investment advice.
Haemonetics stock hits 52-week high at 106.64 USD By Investing.com
Haemonetics Corp (NYSE:HAE) reached a new 52-week high of $106.64, demonstrating strong performance with a 92.73% one-year return. This surge follows better-than-expected fiscal first-quarter results and a new supply agreement with CSL Plasma Inc. Analysts have also revised earnings upwards, indicating continued positive momentum for the company.
Haemonetics Shares Hit New 52-Week High: What's Happening?
Haemonetics Corp (NYSE: HAE) shares surged after the company announced a commercial supply agreement with CSL Plasma Inc. This agreement allows CSL Plasma to adopt Haemonetics’ NexSys PCS devices with Persona PLUS technology across its U.S. network, causing HAE stock to hit a new 52-week high. Following the news, BTIG analyst Marie Thibault reiterated a Buy rating and increased the price target for Haemonetics shares from $96 to $110.
Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating
Barrington has increased its price target for Haemonetics (HAE) to $118 from $95, while maintaining an Outperform rating on the stock. This adjustment follows several recent updates for Haemonetics, including a supply agreement with CSL Plasma and a raised fiscal 2027 outlook after strong Q1 2027 earnings.
Haemonetics Stock Jumped 16% on a CSL Plasma Deal Yesterday. Here’s What Investors Need to Know.
Haemonetics (HAE) stock surged 16% after announcing a non-exclusive supply agreement with CSL Plasma for its NexSys PCS devices and related disposables, a key "razor-and-blade" model expansion. This deal, while lacking minimum purchase commitments, has driven the stock above its consensus analyst price target for the first time in over a year, prompting some analysts to raise their objectives. However, TIKR's valuation model suggests the stock may be overvalued, pricing it at $93 compared to the current $105, arguing the market may have overpaid for the optionality of the deal before concrete financial impacts are announced.
Haemonetics announces non-exclusive supply agreement with CSL Plasma
Haemonetics Corporation (NYSE:HAE) announced a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL Plasma to use Haemonetics’ NexSys PCS devices with Persona PLUS technology for plasma collection. While there are no minimum purchase commitments, Haemonetics expects a portion of CSL Plasma's U.S. centers to transition to these devices. The medical technology company, whose stock has surged 70% over the past year, will provide an update on the agreement's financial impact in November 2026.
Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution?
Haemonetics (HAE) recently reported Q1 results with rising sales but eased net income, alongside filing a $391.25 million shelf registration for ESOP-related shares. This move highlights the company's efforts to balance near-term performance with future funding needs. The article explores how these developments impact Haemonetics' investment narrative, risk profile, and the potential for shareholder dilution, given its existing high valuation and analyst forecasts for growth.
Form 8K Haemonetics Corp For: 18 August By Investing.com
This article from Investing.com is a simple notification about an 8K filing by Haemonetics Corp on August 18. It provides no further details about the content of the filing but lists the company's stock symbol (HAE) and its current performance. The article is largely composed of navigational elements and market data from Investing.com.
Haemonetics Stock Climbs As Analysts Hike Price Targets
Haemonetics Corporation's stock (HAE) has surged by 15.77% after the company reported strong fiscal Q1 earnings, beating revenue and EPS estimates, and raised its FY27 guidance. Several analysts, including Bank of America and Raymond James, have subsequently increased their price targets for HAE, citing best-in-class performance and continued growth in its core franchises. The stock's momentum is driven by its strong fundamentals, high gross margins, and a positive outlook from Wall Street.
Haemonetics Corporation Stock 12‑Month Price Target Raised to $101.8, Implies 13% Upside
Haemonetics Corporation (HAE) has seen its average 12-month price target increased to $101.8 from $99.8 by analysts, suggesting a 13% potential upside from its recent closing price. The consensus rating for the stock remains a "Buy" among 12 covering analysts. Forecasts for the stock range from $86 to $120 per share.
Haemonetics rises after supply deal with CSL
Haemonetics (HAE) shares rose approximately 7% in premarket trading after the company announced a new supply agreement with Australian biopharma firm CSL Limited (CSLLY, CMXHF). The MedTech company, based in Boston, Massachusetts, disclosed the deal in a regulatory filing.
Haemonetics Surges 15.3% After BTIG Maintains Buy
Haemonetics Corporation saw its stock surge 15.3% to $104.05 after BTIG upgraded the medical device maker to a Buy rating and increased its price target from $96 to $110. This upgrade signals increased confidence in the company's market position and growth prospects within the medical devices sector, leading to a significant increase in trading volume and a market capitalization of $4.7 billion. Investors are now watching to see if other analysts will follow BTIG's lead and if the stock can sustain these gains.
Haemonetics announces non-exclusive supply agreement with CSL Plasma
Haemonetics Corporation has entered into a non-exclusive supply agreement with CSL Plasma Inc., allowing CSL Plasma to use Haemonetics’ NexSys PCS devices with Persona PLUS technology. While the agreement has no minimum purchase commitments and its financial impact is still being evaluated, Haemonetics recently reported strong fiscal first-quarter results that exceeded analyst expectations, leading BTIG to raise its price target for the company.
Haemonetics signs non-exclusive U.S. supply deal with CSL Plasma for NexSys PCS devices
Haemonetics has entered a non-exclusive U.S. supply agreement with CSL Plasma to provide NexSys PCS devices with Persona PLUS technology and related disposables. While CSL Plasma may transition some U.S. plasma centers to these devices, the scope and timing are currently undetermined, and Haemonetics is not revising its fiscal 2027 guidance at this time. The company will provide an update on the anticipated impact during its Q2 earnings call in November 2026.
Rice Hall James & Associates LLC Makes New Investment in Haemonetics Corporation $HAE
Rice Hall James & Associates LLC recently invested $3.83 million in Haemonetics Corporation (NYSE:HAE) by purchasing 51,038 shares in the second quarter, contributing to the 99.67% institutional ownership of the stock. Haemonetics exceeded Q2 earnings expectations with adjusted EPS of $1.14 and revenue of $339.38 million. Analysts generally have a "Moderate Buy" rating for HAE, with an average price target of $90.89.
Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance
Haemonetics (HAE) stock has shown strong returns, but its valuation presents a mixed picture. A Discounted Cash Flow (DCF) model suggests it's undervalued by almost 49% based on expected cash flow growth, while its P/E ratio indicates it's overvalued compared to industry averages and a tailored fair P/E. The company's future performance hinges on its ability to deliver on revenue and margin targets without execution issues.
John Rogers's Top Q2 2026 Move: Haemonetics Corp at a 1.54% Portfolio Impact
John Rogers, founder of Ariel Investment, LLC, submitted his Q2 2026 13F filing, revealing strategic portfolio adjustments. His top new buy was Haemonetics Corp (NYSE:HAE), making a 1.54% portfolio impact, alongside significant increases in RLI Corp (NYSE:RLI) and Masco Corp (NYSE:MAS). Rogers also completely exited positions in Stanley Black & Decker Inc (NYSE:SWK) and Microsoft Corp (NASDAQ:MSFT) and reduced stakes in Sphere Entertainment Co (NYSE:SPHR) and Algonquin Power & Utilities Corp (NYSE:AQN).
Assenagon Asset Management S.A. Sells 142,292 Shares of Haemonetics Corporation $HAE
Assenagon Asset Management S.A. significantly reduced its stake in Haemonetics Corporation (NYSE:HAE) by selling 142,292 shares, an 80.2% reduction, leaving them with 35,109 shares valued at $2.6 million. Despite this, institutional investors collectively own 99.67% of HAE, and analyst sentiment remains positive with a "Moderate Buy" consensus and an average price target of $90.89. Haemonetics also exceeded quarterly earnings and revenue expectations, demonstrating strong financial performance.
BofA Securities Adjusts Price Target on Haemonetics to $100 From $93
BofA Securities has increased its price target for Haemonetics (HAE) to $100, up from the previous $93. This adjustment reflects a positive outlook from the firm on the medical technology company. Haemonetics specializes in solutions for critical medical needs, including hospital technologies, plasma collection, and blood management.
Haemonetics (HAE) Q1 2027 Earnings Call Transcript
Haemonetics (HAE) reported a strong Q1 2027 with broad-based growth across all core platforms, leading to raised full-year revenue guidance. The Plasma business showed significant momentum driven by share gains, strong collection trends, and the accelerated rollout of Persona PLUS. The Interventional Technologies segment also returned to growth, primarily due to Vascular Closure device performance and market stabilization.
Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Analysts
Haemonetics Corporation (NYSE:HAE) has received a consensus "Moderate Buy" rating from eleven research firms, with an average 12-month price target of $90.89. The company recently surpassed quarterly expectations, reporting $1.14 EPS and $339.38 million in revenue, leading several analysts to raise their price targets while maintaining or upgrading ratings. Institutional investors hold 99.67% of the stock.
Haemonetics Corp (HAE) Stock Up 4.7% but GF Value Says Overvalued -- GF Score: 77/100
Haemonetics Corp (HAE) shares increased by 4.7% to $91.34, approaching its 52-week high, with significant short-term and long-term momentum. Despite this rise, GuruFocus's GF Value™ indicates the stock is overvalued by 7.6% compared to its estimate of $84.90, suggesting no margin of safety for investors. HAE boasts a GF Score™ of 77/100, reflecting above-average quality driven by strong profitability, but its valuation metrics and lack of recent insider activity point to potential overvaluation.
AQR Capital discloses 4.99% Haemonetics Corp (HAE) position in Schedule 13G/A
AQR Capital Management, LLC and its parent, AQR Capital Management Holdings, LLC, have disclosed a beneficial ownership of 4.99% in Haemonetics Corp (HAE) common stock. This position, totaling 2,266,489 shares, was reported in a Schedule 13G/A filing as of June 30, 2026. The entities share voting power over 2,149,735 shares and shared dispositive power over all 2,266,489 shares.
Quantinno Capital Management LP Has $1.73 Million Stock Holdings in Haemonetics Corporation $HAE
Quantinno Capital Management LP significantly increased its stake in Haemonetics Corporation (NYSE:HAE) by 438% in the first quarter, bringing its total holdings to 30,708 shares valued at $1.73 million. Haemonetics reported strong quarterly results, beating analyst expectations with $339.38 million in revenue and $1.14 EPS, contributing to a "Moderate Buy" consensus rating from analysts. Institutional investors hold a substantial 99.67% of the company's stock, and several analysts have recently raised their price targets for HAE.
Does Strong Q1 Results And VASCADE Data Shift The Bull Case For Haemonetics (HAE)?
Haemonetics Corporation reported stronger-than-expected Q1 results with increased sales and diluted EPS, along with positive new Emory University study data reinforcing the safety and efficiency of its VASCADE MVP XL venous vascular closure system. These developments, particularly the VASCADE data, are seen as significant for strengthening the company's interventional technologies growth engine and could potentially reshape existing pessimistic investment scenarios, despite ongoing concerns about U.S. market concentration and competition. The article suggests that VASCADE's performance is crucial for Haemonetics' investment narrative and future growth.
Haemonetics stock hits 52-week high at 88.73 USD
Haemonetics Corp's stock reached a new 52-week high of $88.73, marking a significant 67.34% increase over the past year and reflecting strong investor confidence. The medical technology company's market capitalization stands at $3.97 billion, with its P/E ratio of 42 suggesting it may be undervalued according to InvestingPro. This achievement follows strong fiscal first-quarter results that surpassed Wall Street expectations, leading BTIG to raise its price target to $96.
